Pathogenesis and treatment of central nervous system demyelinating disease

Revue Neurologique

Volumn 154, Issue 8-9, 1998, Pages 573-575

  Zamvil, S S ^a,b   Soos, J M ^a   Weiner, H L ^a  

^a Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNITY; CONFERENCE PAPER; DEMYELINATING DISEASE; HUMAN; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; PATHOGENESIS; T LYMPHOCYTE;

CENTRAL NERVOUS SYSTEM DISEASES; DEMYELINATING DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0031687552     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. BALASHOV K.E., SMITH D.R., KHOURY S.J., HAFLER D.A., and WEINER H.L. (1997). Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4 + T cells via CD40 ligand. Proc Natl Acad Sci, 94: 509-603.
2. JACOBS L.D., COOKFAIR D.L., RUDICK R.A., HEARNDON R.M., RICHERT J.R., SALAZAR A.M., FISCHER J.S., GOODKIN D.E., GRANGER C.V., SIMON J.H., ALAM J.J., BARTOSZAK D.M., BOURDETTE D.N., BRAIMAN J., BROWNSCHEIDLE C.M., COATES M.E., COHAN S.L, DOUGHERTY D.S., KINKEL R.P., MASS M.K., MUNSCHAUER III F.E., PRIORE, R.L., PULLICINO P.M., SCHEROKMAN B.J., WEINSTOCK-GUTTMAN B., WHITHAM R.H., and The Multiple Sclerosis Collaborative Research Group (M.S.C.R.G.). (1996). Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals Neurol. 39: 285-294.
3. JOHNSON K.P., BROOKS B.R., COHEN J.A., FORD C.C., GOLDSTEIN J., LISAK R.P., MYERS L.W., PANITCH H.S., ROSE J.W., SCHIFFER R.B., VOLLMER T., WEINER L.P., WOLINSKY J.S., and the Copolymer 1 Multiple Sclersois Study Group. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268-1276.
4. NIKCEVICH K.M., GORDON K.B., TAN L., HURST S.D., KROEPFL J.F., GARDINER M., BARRETT T.A., and Miller, S.D. (1997). IFN-g-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J. Immunol. 158: 614-621.
5. SMITH D.R., BALASHOV K.E., HAFLER D.A., KHOURY S.J., and WEINER H.L (1997). Immune deviation following pulse cyclophosphamide/ methylprednisolone treatment of multiple sclerosis: increased IL-4 production and associated eosinophilia. Annals Neurol. 42: 313-318.
6. SOOS J.M., SUBRAMANIAM P.S., HOBEIKA A.C., SCHIFFENBAUER J., and JOHNSON H.M. (1995). The I.F.N. pregnancy recognition hormone I.F.N.-τ blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J. Immunol. 155: 2747-2753.
7. WEINER H.L. (1997). Oral tolerance: immune mechanisms of autoimmune disease, Immunol. Today 19: 335-343.
8. ZAMVIL S.S. and STEINMAN L. (1990). The T lymphocyte in experimental allergic encephalomyelitis. Ann. Rev. Immunol. 8: 579-621.